ZGEN rib/ifn data - The ifn/rib combo data is actually, and somewhat surprisingly, not particularly good compared to the monotherapy data. More AE and equivalent or less efficacy than the monotherapy. At the very least it is likely to make the ph ii trial more complicated because they may want to continue a monotherapy arm in the ph ii.
Also, given the comparatively high rate of SAE in the 1.5 weekly combo arm it is possible that they question going to 3.0 weekly combo. It would be nice to know what they plan on doing inre that possible dose. And kudos to Tony who was worried that going down a dose indicated a problem at the 1.5 combo dosing. There is the appearance of such a problem.
Market Data 
Markets 
AI
